UCART-123 is under clinical development by Cellectis and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how UCART-123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

UCART-123 overview

UCART-123 is under development for the treatment of acute myeloid leukemia, Hodgkin lymphoma. It is administered through intravenous route. The therapeutic candidate acts by targeting CD123 antigen. It is developed based on CAR-T platform technology. It was also under development for the treatment of chronic myelocytic leukemia (CML), hairy cell leukemia (HCL), myelodysplastic syndrome (MDS), blastic plasmacytoid dendritic cell neoplasm and pediatric leukemias.

Cellectis overview

Cellectis, operates as a clinical-stage biopharmaceutical company. It carries out research, develop and commercialize gene editing technology. The company’s pipeline products include UCART22, UCART123, UCART20x22, ALLO-501A 1, ALLO-715 3, ALLO-605 3, ALLO-316 4. z Its pipeline candidates treat Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma, Multiple Myeloma, Renal Cell Carcinoma. Cellectis’s pioneer, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It works in partnership with Allogene Therapeutics, Servier, Iovance Biotherapeutics, Inc, Cytovia Therapeutics, Inc., It operates in New York and Paris. Cellectis is headquartered in Paris, France.

For a complete picture of UCART-123’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.